These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 21068703)

  • 1. A new botulinum toxin (Xeomin) for cervical dystonia and blepharospasm.
    Med Lett Drugs Ther; 2010 Nov; 52(1351):90-1. PubMed ID: 21068703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A guide to dosing in the treatment of cervical dystonia and blepharospasm with Xeomin®: a new botulinum neurotoxin A.
    Pagan FL; Harrison A
    Parkinsonism Relat Disord; 2012 Jun; 18(5):441-5. PubMed ID: 22405829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
    Bihari K
    Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of focal dystonia with botulinum toxin A].
    Sojer M; Wissel J; Müller J; Poewe W
    Wien Klin Wochenschr; 2001; 113 Suppl 4():6-10. PubMed ID: 15506045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.
    Chapman MA; Barron R; Tanis DC; Gill CE; Charles PD
    Clin Ther; 2007 Jul; 29(7):1325-37. PubMed ID: 17825685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dystonia and headaches: clinical features and response to botulinum toxin therapy.
    Galvez-Jimenez N; Lampuri C; Patiño-Picirrillo R; Hargreave MJ; Hanson MR
    Adv Neurol; 2004; 94():321-8. PubMed ID: 14509690
    [No Abstract]   [Full Text] [Related]  

  • 7. [Focal dystonias and facial hemispasm: treatment with botulinum A toxin].
    Astarloa R; Morales B; Sánchez V; Peñafiel N; Rábano J; Oliván J; García de Yébenes J
    Arch Neurobiol (Madr); 1991; 54(5):210-7. PubMed ID: 1804035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Focal dystonias and facial hemispasm: treatment with botulinum A toxin].
    Astarloa R; Morales B; Sánchez V; Peñafiel N; Rábano J; Oliván J; García de Yébenes J
    Arch Neurobiol (Madr); 1991; 54 Suppl 3():44-51. PubMed ID: 1810208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum toxin in blepharospasm and oromandibular dystonia: comparing different botulinum toxin preparations.
    Bhidayasiri R; Cardoso F; Truong DD
    Eur J Neurol; 2006 Feb; 13 Suppl 1():21-9. PubMed ID: 16417594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Xeomin in the treatment of cervical dystonia.
    Benecke R
    Eur J Neurol; 2009 Dec; 16 Suppl 2():6-10. PubMed ID: 20002740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of the FDA-approved uses of botulinum toxins, including data suggesting efficacy in pain reduction.
    Lew MF
    Clin J Pain; 2002; 18(6 Suppl):S142-6. PubMed ID: 12569961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study.
    Marchetti A; Magar R; Findley L; Larsen JP; Pirtosek Z; Růzicka E; Jech R; Sławek J; Ahmed F
    Mov Disord; 2005 Aug; 20(8):937-44. PubMed ID: 15810022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blepharospasm and oromandibular-laryngeal-cervical dystonia: a controlled trial of botulinum A toxin therapy.
    Jankovic J
    Adv Neurol; 1988; 50():583-91. PubMed ID: 3041763
    [No Abstract]   [Full Text] [Related]  

  • 14. Dysport (botulinum toxin type A) in routine therapeutic usage: a telephone needs assessment survey of European physicians to evaluate current awareness and adherence to product labeling changes.
    Hubble J; Schwab J; Hubert C; Abbott CC
    Clin Neuropharmacol; 2013; 36(4):122-7. PubMed ID: 23783005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia.
    Comella CL; Jankovic J; Truong DD; Hanschmann A; Grafe S;
    J Neurol Sci; 2011 Sep; 308(1-2):103-9. PubMed ID: 21764407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin.
    Van den Bergh P; Francart J; Mourin S; Kollmann P; Laterre EC
    Muscle Nerve; 1995 Jul; 18(7):720-9. PubMed ID: 7783762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Botulin in the treatment of local dystonia].
    Domzał T
    Neurol Neurochir Pol; 1992; 26(6):783-9. PubMed ID: 1301505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated.
    Evidente VG; Truong D; Jankovic J; Comella CL; Grafe S; Hanschmann A
    J Neurol Sci; 2014 Nov; 346(1-2):116-20. PubMed ID: 25186131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum toxin therapy for cervical dystonia.
    Jankovic J
    Neurotox Res; 2006 Apr; 9(2-3):145-8. PubMed ID: 16785112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy and tolerability of Xeomin in the treatment of blepharospasm.
    Jankovic J
    Eur J Neurol; 2009 Dec; 16 Suppl 2():14-8. PubMed ID: 20002742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.